Epidemiology, risk factors and outcomes of Acute Kidney Injury (PERFORM-AKI) Study
The incidence of Acute Kidney Injury (AKI) is increasing, with Australian and US Medicare data illustrating striking increases over the decade following 2000. Up to 20% of adult patients experience AKI during their hospitalization, with mortality rates as high as 45%, and AKI is a global healthcare issue that has significant impacts on patients’ quality of life.
At present there are no treatments proven to improve the outcomes of patients with AKI, but there is a large pipeline of promising treatments under development. These treatments have varying mechanisms of action, from anti-inflammatory agents through to apoptosis inhibitors, but will inevitably need clinical trial infrastructure to test their effectiveness.
The PERFORM-AKI study is a prospective cohort study involving patients who are admitted to 4 renal units in New South Wales between January 2021 to December 2021. The study will collect data on the incidence, risk factors, treatments and clinical outcomes of patients with AKI in the non-ICU setting. It will use real-time data collection, in order to understand the clinician’s management of patients at the time they are diagnosed with AKI.